Clinical trial Recruiting at 2 sites Interventional Ages 18 to 80

Does a gluten shake or a gluten cookie produce a stronger immune response in celiac disease?

Official title: Assessing Immune Responses to Gluten: A Comparative Study of Liquid Versus Solid Gluten Administration

Run by Oslo University Hospital · NCT07039773 · Data updated 2026-11-12

This trial tests whether a liquid gluten shake or a solid gluten cookie causes a bigger IL-2 immune response in adults with celiac disease who have been on a gluten-free diet.

More Celiac Disease trials

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment30 (estimated)
SponsorOslo University Hospital
Academic / other
Locations2 sites (Oslo, Oslo and 1 other locations)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedApril 17, 2026
Trial IDNCT07039773 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a prior biopsy-confirmed diagnosis of celiac disease who have adhered to a strict gluten-free diet for at least 12 months, have BMI 18–33 kg/m2, and meet the study screening labs and safety criteria are ideal candidates.

Probably not a fit

People with ongoing positive celiac serology, active inflammatory or systemic illnesses, pregnant or breastfeeding women, children, or those unable to attend the Oslo clinic visits are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with biopsy-proven celiac disease who have followed a strict gluten-free diet will undergo two supervised gluten challenges — one with a liquid shake and one with a solid cookie — given in randomized order at least four weeks apart. Blood samples will be collected before and after each challenge to measure serum IL-2 and gluten peptide concentrations over time. The study compares the magnitude and timing of the IL-2 cytokine response between the two formulations to see if one elicits a stronger or faster immune signal. Findings will inform which gluten formulation is most sensitive for provoking measurable immune responses in controlled challenge settings.

Why it matters

Potential benefit: If successful, the results could help standardize gluten-challenge methods and improve detection of immune responses in celiac disease, which may speed research and improve monitoring.

How similar studies have gone: Previous gluten challenge studies have shown rapid, measurable IL-2 rises after gluten exposure, so this work builds on existing findings but specifically compares liquid versus solid formulations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* BMI 18-33 kg/m2
* Willingness to comply with the study procedure and having signed informed, written consent
* Previous diagnosis of coeliac disease according to established guidelines based on positive serology (Endomysium test, IgA-TG2 and/or IgG-DGP) (diagnosed in childhood) and a duodenal biopsy showing villous atrophy graded as Marsh 3 according to guidelines from European Society for Study of Coeliac Disease .
* Strict adherence to a gluten-free diet at least the 12 last months.

Exclusion Criteria:

* Positive serology (IgA-TG2 below upper level of normal) at screening visit
* Pregnancy or breast feeding. Fertile women must use effective contraception.
* Other inflammatory disease like uncontrolled hypothyreosis, type 1 diabetes, cardiovascular diseases, thyroid and renal disorders, inflammatory bowel diseases or any other disease that in the opinion of the responsible clinician makes the patient unsuitable for the study
* Using of immunosuppressive/steroid medications
* Wheat allergy
* Severe acute infection

Where it's running

  • Oslo University Hospital
    Oslo, Oslo, Norway
    Recruiting
  • Lovisenberg Diakonale Hospital
    Oslo, Oslo, Norway
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.